Compass Therapeutics (CMPX)

• Market cap: $193M
• 1 day: -3.45%
• 5 days: -6.67%
• 1 month: -15.66%
• 3 months: -27.08%
• 6 months: 59.09%
• Year to date: -5.41%
• 1 year: -5.41%
• 5 years: -64.82%
• 10 years: -64.82%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Employees: 32

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

81% more capital invested

Capital invested by funds: $93.6M [Q2] → $170M (+$76.1M) [Q3]

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.61% less ownership

Funds ownership: 67.65% [Q2] → 67.03% (-0.61%) [Q3]

4% less funds holding

Funds holding: 82 [Q2] → 79 (-3) [Q3]

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 614% upside
• Avg. target: $21 1,400% upside
• High target: $32 2,186% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 30% 1-year accuracy 48 / 159 met price target	2,186% upside $32	Buy Initiated	23 Dec 2024
HC Wainwright & Co. Joseph Pantginis 25% 1-year accuracy 97 / 384 met price target	614% upside $10	Buy Reiterated	15 Nov 2024